Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
The Protein Analytical group at Jounce Therapeutics is looking for an individual with expertise in protein therapeutics, especially in the fields of antibody characterization/developability assessment and protein affinity determination. This is an exciting opportunity to play an important role in the discovery and development of novel biotherapeutics for immuno-oncology. The successful candidate will be the protein analytical lead on project teams, lead experimental design, conduct experiments, optimize throughput, maintain detailed records, and generate standard operating procedures. In this role you will have the opportunity to work cross functionally across multiple departments including discovery/biology, pre-clinical, Ab technology, protein production and CMC.
The candidate will have strong protein biochemistry and antibody discovery knowledge and be proficient at designing and executing lab experiments.
Jounce Therapeutics is an equal opportunity employer and does not discriminate in it’s employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.
To apply, please visit https://careers-jouncetx.icims.com/.